New R&D collaboration to advance Alport Syndrome programme


Fibrocor Therapeutics has entered into a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome programme.

The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase Ib. MSRD, a member of the Otsuka family of pharmaceutical companies, identifies and supports early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders.

FIB918 is now in the IND-enabling phase and Phase I clinical trials of the monoclonal antibody are targeted to start in late 2025. Fibrocor and MSRD will be working with patients, advocacy groups and regulators to execute safe, effective and inclusive clinical trials that take patient input and lifestyle into consideration, aiming to positively shift the clinical and treatment paradigm for patients.

William Newsome, CEO, President of Fibrocor said: “This collaboration with the experienced team at MSRD, coupled with research funding, represents continued validation of Fibrocor’s translational, best-in-class, target discovery platform. It represents hope and potential for individuals grappling with Alport Syndrome worldwide. FIB918 has the potential to deliver a significant advancement in the treatment of patients afflicted by this debilitating disease, where current options are limited. The completion of our Investigational New Drug (IND) application and the anticipated commencement of clinical trials in 2025, mark crucial milestones in our journey to make a meaningful impact on the lives of those affected by Alport Syndrome.”

Piet Wigerinck, Chief Scientific Advisor of Fibrocor, confirmed that this will be followed by the initiation of clinical trials for FIB991 for chronic allograft nephropathy in 2025.

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free